Brentwood, May 1 2013: Martindale Pharma, a leader in the manufacture and supply of specialty pharmaceuticals, is pleased to announce the UK launch of Tapclob 5mg/5ml and Tapclob 10mg/5ml Oral Suspension, the first licensed oral liquid suspension version of clobazam. Supplies of this widely used and much needed oral liquid version of clobazam are now available to fulfill prescriptions.
Tapclob will be distributed exclusively by Alliance Healthcare Distribution Limited.
Tapclob 5mg/5ml and 10mg/5ml Oral Suspension (clobazam oral suspension) will be used principally as an adjunctive therapy for epilepsy, with the majority of use believed to be in children. It is an off-white oral solution presented in a 150ml glass bottle in two strengths 5mg/5ml and 10mg/5ml to maximise flexibility of dosing. Tapclob has the same indications as clobazam tablets. This new licensed oral liquid version of clobazam not only allows for better ease of use, especially for paediatrics, but also provides healthcare professionals with a much needed replacement to prescribing expensive, unlicensed ‘special’ versions of clobazam oral liquid products.
Richard de Souza, Chief Executive Officer of Martindale Pharma commented, “We are pleased to have launched the first ever licensed oral liquid formulation of clobazam in the UK. More than half a million people in the UK suffer from epilepsy, and this new formulation will allow both prescribers and patients to access a safe and cost-effective licensed oral liquid formulation when required. Tapclob has been developed using our extensive knowledge of oral liquid formulations, in line with our commitment to provide high quality innovative products to our customers and to patients, and ensuring cost-effectiveness for the NHS.”
For further information on Tapclob 5mg/5ml and 10mg/5ml Oral Suspension please contact Martindale Pharma on 0800 0287933 or our Medical Information Team on 01708 382145 or via medinfo@martindalepharma.co.uk.
About Martindale Pharma®
After starting out as a London chemist store owned by William Martindale, Martindale Pharma has remained in business for more than a century and is now firmly established as a leading supplier to the UK’s NHS and exports its products to a number of other major pharmaceutical markets.
In May 2010 AAC Capital bought Martindale Pharma from Cardinal Health. AAC Capital continues to develop the business and pursue growth opportunities.
Martindale Pharma manufacture the majority of their products at their own facilities in the UK, in total producing and packing c.50 million doses a year in a range of formats including sterile ampoules/vials, oral solutions, pre-filled syringes, suppositories and ophthalmics.
Martindale Pharma’s key business segments are:
• Specials
• Critical Care
• Ophthalmics
• Hospital Specialty Products
• Addiction
For further information visit www.martindalepharma.co.uk
Media contacts:
Martindale Pharma
Michael Clark
Tel: +44 (0) 1277 235300
M:Communications
Mary Clark / Amber Bielecka / Hollie Vile
Tel : +44 (0) 207 920 2361
Help employers find you! Check out all the jobs and post your resume.
